•  DELIVER

early feasibility study to evaluate the safety and performance of intravascular hepatic denervation using the Metavention Integrated Radio Frequency Denervation System (iRF System) to improve glycemic control in type 2 diabetes subjects.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

www.clinicaltrials.gov/ct2/show/NCT04285554

  • NN9535-4533 – Type 2 Diabetes & PAD

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE) – This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04560998

  • GPGN – Type 2 Diabetes

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT) – The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04255433?titles=SURPASS-CVOT

  • Dompe – Type I Diabetes

The objective of this clinical trial is to assess whether ladarixin treatment is effective in preserving beta-cell function and delaying the progression of type 1 diabetes (T1D) in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated. The study is planned to involve -327 patients with new-onset T1D, to include about 200 adolescents (14-17 years). Patients will be randomly (2:1) assigned to receive either ladarixin treatment (400 mg b.i.d. for 13 cycles of 14 days on/14 days off – treatment group) or matched placebo (control group). The two groups will be balanced within centers.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT04628481

  • EX6018-4758 ZEUS

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.  Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same.  Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe.

Participants will get the study medicine in a pre-filled syringe. Participants will need to use the pre-filled syringe to inject the study medicine into a skinfold once-monthly.

The study is expected to last for up to 4 years. Participants will have blood and urine samples taken at most of the clinic visits.  Participants will have their heart examined using sound waves (echocardiography) and electrodes (electrocardiogram).

Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT05021835

    More Coming Soon